NQMC Update Service: November 11, 2013 ▲ American Society for Blood and Marrow Transplantation

NQMC Update Service: November 11, 2013

American Society for Blood and Marrow Transplantation

November 11, 2013

NQMC Update Service: November 11, 2013

Agency for Healthcare Research and Quality (AHRQ) sent this bulletin at 11/11/2013 12:00 PM EST

November 11, 2013

New This Week

Measure Summaries

American Society for Blood and Marrow Transplantation

• Chronic graft versus host disease (cGVHD): percentage of patients diagnosed with cGVHD with a standardized scoring system used to plan therapy.

• Chronic graft versus host disease (cGVHD): percentage of patients diagnosed with cGVHD with diagnosis confirmed with at least one diagnostic manifestation or one distinctive manifestation with confirmation by pertinent biopsy, lab tests or radiology in the same or different organ.

• Chronic graft versus host disease (cGVHD): percentage of patients with cGVHD who received calcium and vitamin D level testing within 3 months of diagnosis.

• Chronic graft versus host disease (cGVHD): percentage of patients with cGVHD who were prescribed pneumococcal prophylaxis.

• Chronic graft versus host disease (cGVHD): percentage of patients with moderate or severe cGVHD with systemic immunosuppressive therapy prescribed.

• Chronic graft versus host disease (cGVHD): percentage of patients with symptomatic mild cGVHD with only local therapy prescribed.

• Infection control after hematopoietic cell transplantation (HCT): percentage of patients confirmed to have a dental exam done by a dentist prior to undergoing HCT.

• Infection control after hematopoietic cell transplantation (HCT): percentage of patients who had HCT and family members/household contacts receiving recommendations for annual seasonal influenza vaccinations.

• Infection control after hematopoietic cell transplantation (HCT): percentage of patients who had HCT and receiving recommendation for annual seasonal influenza vaccination with trivalent inactivated vaccine.

• Infection control after hematopoietic cell transplantation (HCT): percentage of patients who had HCT and were at risk for cytomegalovirus (CMV) and were prescribed a CMV disease prevention program for 100 days after HCT.

• Infection control after hematopoietic cell transplantation (HCT): percentage of patients who had HCT and were herpes simplex virus seropositive and/or varicella-zoster virus seropositive and prophylaxis was prescribed.

• Infection control after hematopoietic cell transplantation (HCT): percentage of patients who were expected to be neutropenic for 7 or more days during HCT and were prescribed antibacterial prophylaxis with a fluoroquinolone.